Redefining Platinum Sensitivity : Additional Treatment Considerations in a Changing Paradigm

Description

Listen to this new presentation by Dr. Robert Coleman with moderation by Dr. Floor Backes and Dr. Wendel Naumman. Dr. Coleman explores the evolving treatment strategies for recurrent platinum-sensitive ovarian cancer, drawing on the latest clinical trial data and real-world outcomes. The session revisits the current treatment landscape, highlights future directions, and examines how these developments are shaping patient care moving forward.

Presented by:

A person in a suit and tieDescription automatically generated

Robert Coleman, MD, FACOG, FACS
Chief Medical Officer
Vaniam Group
USA

Moderated by:

	Floor Backes, MD The Ohio State University Wexner Medical Center James Comprehensive Cancer Center USA
	Wendel Naumann, MD Director of Minimally Invasive Surgery in Gynecologic Oncology Carolinas Medical Center Associate Medical Director of Clinical Trials Levine Cancer Institute, Atrium Health USA

Attended previous IGCS webinars? If you have attended IGCS webinars in the past, you may already have an IGCS account and creating a new account is not required. If unsure of your login information, you may reset your information by selecting "Forgot Password" at login or contact education@igcs.org.

Supported in part by

Summary

Availability:

On-Demand

Cost:

FREE

Create Account

Recommended

Personalized Management of Advanced or Recurrent Endometrial Cancers: Navigating pMMR, dMMR Subtypes, or Molecular Classifications

FREE

IGCS 2024 Endometrial Cancer Master Session

FREE

Journal Club: The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial

FREE

Genetic Testing for Lynch Syndrome in Endometrial Cancer

FREE

Patient reported outcomes exploring quality of life in PROC and novel therapeutics: mirvetuximab in recurrent ovarian cancer

FREE

Journal Club:Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE)

FREE

IGCS 2024 Ovarian Master Sessions: The Era of Targeted Therapies

FREE

Journal Club - Surgical versus clinical staging prior to primary chemoradiation in patients with cervical cancer FIGO stages IIB–IVA

FREE

Journal Club: Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

FREE